Study of m-RESIST, an m-Health Program for Treatment-resistant Schizophrenia

Schizophrenia Clinical Trial

— m-RESIST  

Official title:

Pilot Study of m-RESIST, an m-Health Program for Treatment-resistant Schizophrenia: Acceptability, Usability, Satisfaction and Perceived Quality of Life Reported by Patients and Caregivers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03064776
• Other study ID #: IIBSP-RES-2016-51
• Secondary ID: 643552
• Status: Completed
• Phase: N/A
• Start date: March 1, 2017
• Est. completion date: June 1, 2019

Study information

• Verified date: June 2019
• Source: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

m-RESIST is an m-health intervention program aimed to develop, test and evaluate a tool to allow patients suffering from treatment-resistant schizophrenia to self-manage their condition. This may facilitate acceptance and involvement of patients with their own treatment, as well as of caregivers. Moreover this programme could provide a new tool to the psychiatrist, psychologists working together with other health care professionals, to better monitor patients, through a personalised and optimised therapeutic process. The present document corresponds to the pilot field-trials phase included in a three year European research project, co-funded by the Horizon 2020 Framework Programme of the European Union (grant agreement nº 643552). This document summarises the protocol of the whole therapeutic process, specifying all the procedures included in the program. This protocol will be implemented in three countries: Israel, Hungary and Spain, in order to test acceptability, usability, satisfaction and changes in the quality of life reported by the end-users.

Description:

The main goal of the present study is to evaluate the acceptability, usability, and satisfaction to m-RESIST solution among the target groups (patients, caregivers, clinicians), and also to evaluate the effect of m-RESIST solution to empowerment and perceived quality of life of the treatment-resistant Schizophrenia patients (TRS). Interventions targeting key problems in TRS (risk behaviours, persistent symptoms of psychosis, poor medication adherence, unhealthy lifestyle habits) will be administered in a clinical setting, with the long-term goal of creating a widely-available system that can be deployed by users as needed, in their own environments. The study will be conducted in three different regions: Gertner (Israel), Semmelweis (Hungary) and Barcelona (Spain). Consequently, the outcomes obtained in each site and their comparison will allow improving the m-RESIST program in terms of interoperability, integration of components and final implementation of the interactive system in the healthcare pathways. The participants will be selected from Sheba Medical Center - Psychiatric Division (Tel Aviv), Semmelweis University - Department of Psychiatry and Psychotherapy (Budapest), and the adult psychiatric outpatient service of Hospital de la Santa Creu i Sant Pau (Barcelona). A total of 45 patients with TRS (15 per centre), with their caregiver, will be included in the trial. All participants will be fully informed about the nature of the study (aims, methodology) and the system tested (data protection, expected risks/benefits, possible adverse events) and they will sign the informed consent for their participation in this study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 43
• Est. completion date: June 1, 2019
• Est. primary completion date: July 1, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Diagnosis of Schizophrenia following the diagnostic and statistical manual of mental disorders (DSM-V) criteria.
• Meet criteria for "treatment-resistant schizophrenia", term referred to two different

subgroups of patients:

• Patients with schizophrenia who are refractory despite receiving antipsychotic treatment in suitable doses and duration (at least two dopamine D2 receptors antagonist antipsychotics, or on-going treatment with clozapine due to meeting treatment-resistant criteria), and presenting good adherence to treatment (Peuskens, 1999).
• Patients who may be considered pseudo-resistant to the treatment or resistance-like (Elkis & Meltzer, 2007). In this case, presence of active symptoms may be influenced by psychiatric and medical conditions such as poor insight, negative attitude to medication, social isolation, consumption of toxic substances, presence of nutritional and medical problems, inappropriate health habits, as well as poor alliance and/or environment conditions (low involvement of caregivers in the therapeutic process), which may substantially contribute to poor responses or insufficient effects of medication.
• Duration of disease less than 15 years.
• Used to Information and Communication Technologies (ICT) and having the physical capability to use them (determined using the Technological Readiness Questionnaire).
• Presence of a informal caregiver -family members or significant others- of patients with treatment-resistant schizophrenia.

Exclusion Criteria:

• Meet criteria for remission according to the Remission of Schizophrenia Working Group (Andreasen et al., 2005.)
• The presence of delusions mainly related with their therapists or with new technologies.
• Hearing, vision, or motor impairment that makes it impossible to operate a smartphone.
• Presence of a caregiver or Informal carer not used to ICT or physical incapability to use them (determined using the Technological Readiness Questionnaire).
• Presence of intellectual developmental disability.-

Related Conditions & MeSH terms

• Schizophrenia

Intervention

Device:
• m-RESIST Patients
A mobile system based on Information and Communications Technology (ICT), which is addressed to empower patients suffering from TRS and to involve their caregivers
• m-RESIST Caregivers
A mobile system based on Information and Communications Technology (ICT), which is addressed to empower patients suffering from TRS and to involve their caregivers

Locations

Country	Name	City	State
Hungary	3Department of Psychiatry and Psychotherapy, Semmelweis University	Budapest
Israel	The Gertner Institute of Epidemiology and Health Policy Research, Sheba Medical Center	Tel Aviv
Spain	Department of Psychiatry. Hospital Santa Creu i Sant Pau	Barcelona

Sponsors (5)

Lead Sponsor	Collaborator
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau	AQuAS, Agència de Qualitat i Avaluació Sanitàries, iMinds, Semmelweis University, Sheba Medical Center

Countries where clinical trial is conducted

Hungary,  Israel,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Technology Acceptance Model (TAM)		Changes from baseline scores at 1-month and 3-months scores
Secondary	Change in User Experience Questionnaire		Changes from baseline scores at 1-month and 3-months scores
Secondary	Change in EuroQol-5D Health Questionnaire (EQ-5D)		Changes from baseline scores at 1-month and 3-months scores
Secondary	Change in Client Satisfaction Questionnaire (CSQ-8)		Changes from baseline scores at 1-month and 3-months scores
Secondary	Change in Positive and Negative Syndrome Scale for Schizophrenia (PANSS)		Changes from baseline scores at 1-month and 3-months scores
Secondary	Change in Neuropsychological Assessment		Changes from baseline scores at 1-month and 3-months scores
Secondary	Change in Clinical Global Impression-Schizophrenia (CGI-SCH)		Changes from baseline scores at 1-month and 3-months scores
Secondary	Change in Social Functioning Scale (SFS)		Changes from baseline scores at 1-month and 3-months scores